Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock
Shares outstanding
165,974,436
Total 13F shares
60,495,199
Share change
+614,155
Total reported value
$133,691,334
Put/Call ratio
92%
Price per share
$2.21
Number of holders
140
Value change
+$1,259,202
Number of buys
83
Number of sells
45

Institutional Holders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) as of Q1 2024

As of 31 Mar 2024, Xeris Biopharma Holdings, Inc. - Common Stock (XERS) was held by 140 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 60,495,199 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, CAXTON CORP, MPM BIOIMPACT LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, Rosalind Advisors, Inc., MILLENNIUM MANAGEMENT LLC, Nuveen Asset Management, LLC, and CenterBook Partners LP. This page lists 140 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.